Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023:186:71-89.
doi: 10.1007/978-3-031-30065-3_5.

Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer

Melissa M Pham  1 , Monica Avila  1   2 , Emily Hinchcliff  3 , Shannon N Westin  4
Affiliations

Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer

Melissa M Pham et al. Cancer Treat Res. 2023.

Abstract

The treatment of ovarian cancer has remained a clinical challenge despite high rates of initial response to platinum-based chemotherapy. Patients are generally diagnosed at an advanced stage with significant disease burden, which portends to worse survival outcomes. Deficiencies in the homologous recombination (HRD) DNA damage repair (DDR) pathway and mutations in the BRCA1/2 genes have been found in ovarian carcinomas. Moreover, patients with these specific molecular aberrations have demonstrated sensitivity and thus improved response to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment. The results of various clinical trials exploring the use of PARPi in different populations of ovarian cancer patients have shown impressive survival and response outcomes. With expanding indications, the use of PARPi has thus changed the landscape of ovarian cancer treatment. In this chapter, we will describe the different settings of PARPi treatment-frontline maintenance therapy, maintenance therapy for patients with recurrent platinum-sensitive disease, and treatment in the recurrent setting-and discuss treatment considerations and management of toxicities, as well as offer thoughts on future directions.

Keywords: Frontline maintenance; Maintenance therapy; Ovarian cancer; PARP inhibitors; Recurrent disease.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7–33 - DOI - PubMed
    1. Peres LC, Sinha S, Townsend MK, Fridley BL, Karlan BY, Lutgendorf SK et al (2021) Predictors of survival trajectories among women with epithelial ovarian cancer. Gynecol Oncol 156(2):459–466 - DOI
    1. Ledermann J, Harter P, Gourley C et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382–1392 - DOI - PubMed
    1. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26):2495–2505 - DOI - PubMed
    1. Paoletti X, Lewsley L, Daniele G, Cook A, Yanaihara N et al (2020) Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer. JAMA Netw Open

MeSH terms

LinkOut - more resources